BioCentury
ARTICLE | Company News

Dynavax submits Heplisav MAA

July 25, 2012 1:52 AM UTC

Dynavax Technologies Corp. (NASDAQ:DVAX) submitted an MAA to EMA for Heplisav to prevent HBV infection caused by all known subtypes in adults ages 18-70 years and in patients with chronic kidney disea...